251 related articles for article (PubMed ID: 9725779)
1. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis.
Yoshimoto K; Saima S; Nakamura Y; Nakayama M; Kubo H; Kawaguchi Y; Nishitani H; Nakamura Y; Yasui A; Yokoyama K; Kuriyama S; Shirai D; Kugiyama A; Hayano K; Fukui H; Horigome I; Amagasaki Y; Tsubakihara Y; Kamekawa T; Ando R; Tomura S; Okamoto R; Miwa S; Koyama T; Echizen H
Clin Nephrol; 1998 Aug; 50(2):90-3. PubMed ID: 9725779
[TBL] [Abstract][Full Text] [Related]
2. A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis.
Yoshimoto K; Saima S; Echizen H; Nakamura Y; Ishizaki T
Clin Nephrol; 1993 Aug; 40(2):114-7. PubMed ID: 8222367
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide is a marker of peritonitis in patients on continuous ambulatory peritoneal dialysis.
Choi KC; Jeong TK; Lee SC; Kim SW; Kim NH; Lee KY
Adv Perit Dial; 1998; 14():173-9. PubMed ID: 10649719
[TBL] [Abstract][Full Text] [Related]
4. Clinical case: Peritoneal dialysis patient with cloudy peritoneal fluid following administration of calcium antagonists.
Viñolo López MC; Gutiérrez Rivas PC; Liébana Cañada A; Gil Cunquero JM; Merino García E
Nefrologia; 2011; 31(5):624. PubMed ID: 21959742
[No Abstract] [Full Text] [Related]
5. [Possible role of Lercanidipine in Chiloperitoneum occurrence in CAPD: a case-report].
Nicotera R; Chiarella S; Placida G; De Paola L; D'Onofrio G; Panzino MT; Panzino A; Mileti S; Pinciaroli AR; Coppolino G
G Ital Nefrol; 2018 Jul; 35(4):. PubMed ID: 30035445
[TBL] [Abstract][Full Text] [Related]
6. Treatment of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis.
Horton MW; Deeter RG; Sherman RA
Clin Pharm; 1990 Feb; 9(2):102-18. PubMed ID: 2407420
[TBL] [Abstract][Full Text] [Related]
7. Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review.
Kim S; Yu YM; Kwon J; Yoo H; Jung SH; Lee E
Int J Environ Res Public Health; 2019 Apr; 16(8):. PubMed ID: 31013922
[TBL] [Abstract][Full Text] [Related]
8. Incidence of gingival hyperplasia caused by calcium antagonists in continuous ambulatory peritoneal dialysis patients.
Shouda J; Nakamoto H; Sugahara S; Okada H; Suzuki H
Adv Perit Dial; 1999; 15():153-5. PubMed ID: 10682092
[TBL] [Abstract][Full Text] [Related]
9. Calcium channel blocker-induced chylous ascites in peritoneal dialysis.
Tsao YT; Chen WL
Kidney Int; 2009 Apr; 75(8):868. PubMed ID: 19337227
[No Abstract] [Full Text] [Related]
10. Is interleukin-6 concentration in the dialysate of continuous ambulatory peritoneal dialysis patients a prognostic parameter in peritonitis?
Fiedler R; Schneider I; Fischer K; Deuber HJ; Osten B
Adv Perit Dial; 2001; 17():159-62. PubMed ID: 11510267
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of the epidemiological, clinical and laboratory findings in continuous ambulatory peritoneal dialysis related peritonitis attacks].
Bulut C; Oztürk R; Yilmaz GR; Parpucu H; Irmak H; Kinikli S; Duranay M; Demiröz AP
Mikrobiyol Bul; 2008 Apr; 42(2):255-64. PubMed ID: 18697423
[TBL] [Abstract][Full Text] [Related]
12. The value of low-dose intraperitoneal immunoglobulin administration in the treatment of peritoneal dialysis-related peritonitis.
Coban E; Ozdogan M; Tuncer M; Bozcuk H; Ersoy F
J Nephrol; 2004; 17(3):427-30. PubMed ID: 15365965
[TBL] [Abstract][Full Text] [Related]
13. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
Gallar P; Ortega O; Gutiérrez M; Muñoz M; Hilara L; Oliet A; Rodríguez I; Giménez E; Vigil A
Nefrologia; 2000; 20(4):355-61. PubMed ID: 11039261
[TBL] [Abstract][Full Text] [Related]
14. [The effect of the number of peritonitis episodes on peritoneal membrane function].
Jovanović D; Nesić V; Dimitrijević Z
Srp Arh Celok Lek; 1999; 127(1-2):28-31. PubMed ID: 10377837
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
[TBL] [Abstract][Full Text] [Related]
16. Evolving appendicitis presenting as culture-negative peritonitis with minimal symptoms in a patient on continuous ambulatory peritoneal dialysis.
Lee YJ; Cho AJ; Lee JE; Huh W; Kim YG; Oh HY; Kim DJ
Ren Fail; 2010; 32(7):884-7. PubMed ID: 20662704
[TBL] [Abstract][Full Text] [Related]
17. Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate.
Lee F; Yu MC
Am J Kidney Dis; 2009 Mar; 53(3):e1-3. PubMed ID: 19167800
[TBL] [Abstract][Full Text] [Related]
18. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
19. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic eosinophilic peritonitis in continuous ambulatory peritoneal dialysis: experience with percutaneous catheter placement.
Jo YI; Song JO; Park JH; Lee JH; Shin SK
Nephrology (Carlton); 2007 Oct; 12(5):437-40. PubMed ID: 17803465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
